Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases

Area of Science:

• Immunology
• Cell Biology
• Rheumatology

Background:

• Systemic autoimmune diseases result from a loss of self-tolerance and immune homeostasis.
• Current treatments for autoimmune diseases often involve broad immunosuppression or targeted therapies that rarely restore immune tolerance.
• Limitations of existing therapies necessitate the exploration of novel approaches.

Purpose of the Study:

• To review novel cell-based therapeutic strategies for systemic autoimmune diseases.
• To introduce and discuss three key cell types with immune-regulatory properties: mesenchymal stromal cells, regulatory T cells (Tregs), and myeloid-derived suppressor cells.
• To examine the cellular characteristics, immune regulatory mechanisms, and clinical/preclinical data of these cell therapies.

Main Methods:

• Review of recent scientific literature on cell therapies for autoimmune diseases.
• Analysis of preclinical and clinical study data for mesenchymal stromal cells, Tregs, and myeloid-derived suppressor cells.
• Discussion of the challenges and limitations associated with each cell therapy approach.

Main Results:

• Mesenchymal stromal cells, Tregs, and myeloid-derived suppressor cells possess immunosuppressive features and immune-regulatory mechanisms.
• These cell types have demonstrated potential in preclinical and clinical studies for attenuating autoimmunity.
• Significant advancements in biotechnology allow for the in vitro expansion and manipulation of these cells for therapeutic purposes.

Conclusions:

• Cellular therapies offer a promising avenue for inducing immune tolerance in patients with systemic autoimmune diseases.
• Further research and clinical trials are needed to overcome challenges and optimize the application of mesenchymal stromal cells, Tregs, and myeloid-derived suppressor cells.
• These 'tolerogenic' cell populations represent a potential paradigm shift in autoimmune disease treatment.